Stay updated with breaking news from Pfizer Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer is shelving development of a twice-daily version of its weight loss drug after a trial proved users reported high rates of adverse side effects.
Pfizer’s twice-daily GLP-1 danuglipron reached its primary endpoint in a Phase 2b trial, but caused high rates of side effects like nausea and vomiting.
:max_bytes(150000):strip_icc()/GettyImages-534265154-6586d7cc047c4740bf2737cc7653e9aa.jpg)
Pfizer shares lost ground after ending a study of a twice-a-day weight-loss pill because of negative side effects.
Pfizer said Friday it is halting the testing of a twice-daily obesity drug, citing side effects. The company said in a press release it will now focus its future efforts for the drug, danuglipron, on a “once-daily formulation.” It noted high rates of adverse reactions to the twice-daily formulation in its Phase 2b clinical trial…
Pfizer Inc. invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences: Annaliesa Anderson, SVP & Head, Vaccines Research...